fered by 1.0 nmol/L or more. These samples came from 13 patients: 10 men, three women, ages 70 ± 12 years. The only drugs being taken in common, apart from digoxin, were furosemide (10 patients) and amiloride (four patients We have modified the Clinical Assays (Travenol-Genentech Diagnostics, Cambridge, MA) Alpha-Fetoprotein RIA kit procedure to enhance low-end sensitivity without compromising high-end sensitivity. The Clinical Assays AFP kit is a conventional double-antibody RIA procedure. We tried several experimental approaches. The modification that satisfied our requirements consisted of changing the original protocolto a sequential scheme with a 1-h incubationof samples,standards, and controls with the anti-AFP antibody, followed by addition of the I tracer and further incubation for 2 h. All incubationswere at room temperature and the volumes used were those specified in the original standard protocol. We evaluated a total of 63 patients and three controls by both the standard and sequential scheme for correlation. The coefficientof correlation (r) was 0.99, r2 = 0.98. The equation for the regression linewasy = 0.92x + 6.62,whereyisthesequentialandxis the standard protocol. The calculated sensitivity, based on 20 replicates of the zero standard, was 1.1 int. units/mL for the sequential compared with 8.0 mt. unita/mL for the standardprotocol. The standard curve was alsomodifiedto include a 5.0 int. units/mL standard and the 400 int. units/mL standard was deleted. The range of the standard curve was 0 to 200 int. units/mL. We believe this sequential procedure offers significant advantages of precision and accuracy over the standard protocol. 
MSAFP results are reported in terms of the multiple of the median (MoM). By integrating maternal age and MSAFP, it canbe seen that a pregnant woman at age 20 years with an MSAFP of 9 int. unita/inL (0.35 MoM) at 16 weeks or a 34-year-old with an MSAFP of 19 int. unita/mL (0.72 MoM) at 16 weeks has a risk for a fetus with Down syndrome equivalent to that for a 35-year-old woman based on age alone. Most commercial kits are not adequately sensitive in the low range, and inaccurate assay results not only can have seriouspsychological effects but also incur additional costly diagnostic tests to the patient.
We have modified the Clinical Assays (Travenol-Genentech Diagnostics, Cambridge, MA) Alpha-Fetoprotein RIA kit procedure to enhance low-end sensitivity without compromising high-end sensitivity. The Clinical Assays AFP kit is a conventional double-antibody RIA procedure. We tried several experimental approaches. The modification that satisfied our requirements consisted of changing the original protocolto a sequential scheme with a 1-h incubationof samples,standards, and controls with the anti-AFP antibody, followed by addition of the I tracer and further incubation for 2 h. All incubationswere at room temperature and the volumes used were those specified in the original standard protocol. We evaluated a total of 63 patients and three controls by both the standard and sequential scheme for correlation. The coefficientof correlation (r) was 0.99, r2 = 0.98. The equation for the regression linewasy = 0.92x + 6.62,whereyisthesequentialandxis the standard protocol. The calculated sensitivity, based on 20 replicates of the zero standard, was 1.1 int. units/mL for the sequential compared with 8.0 mt. unita/mL for the standardprotocol. The standard curve was alsomodifiedto include a 5.0 int. units/mL standard and the 400 int. units/mL standard was deleted. The range of the standard curve was 0 to 200 int. units/mL. We believe this sequential procedure offers significant advantages of precision and accuracy over the standard protocol. 
U.K.)
Determinationof small increases above normal of albumin in diabetic urine has been reported as indicating early, still reversible, diabetic nephropathy. A simple, rapid method for assaying large numbers of urines at low cost has been developed for use with the Encore centrifugal analyzer (Baker Instruments Ltd, Egham, Surrey, U.K.).
To evaluate the method, we used calibration material of human origin for specific protein assay (SPS-01) from the Protein Reference Unit, Royal Hallamshire Hospital, Sheffield, U.K., for preparing the standard curve. Goat antibodies to albumin from the same source (specific antibody concentration 10.5 mg/L) was diluted 40-fold with polyethylene glycol 6000 (PEG) in isotonic saline (NaCl 150 mmol/L). The diluent wash was PEG 35 g/L, in distilled water. Turbid urines were ifitered before analysis. The reagent blank contained all reagents, but isotonic saline was substituted for urine. Volumes were: sample 18 L; antibody 230 L; diluent 30 zL. The temperature was 30#{176}C, wavelength 340 nm. Curve fit was by cubic spline. Absorbance was read at 100 s, then at 2-s intervals until it no longer increased. 
